EPIRUS Biopharmaceuticals EPRSQ Stock
EPIRUS Biopharmaceuticals Price Chart
EPIRUS Biopharmaceuticals EPRSQ Financial and Trading Overview
EPIRUS Biopharmaceuticals stock price | 0.0000 USD |
Previous Close | 1.0E-6 USD |
Open | 1.0E-6 USD |
Bid | 0.15 USD x 5000 |
Ask | 0.16 USD x 70000 |
Day's Range | 1.0E-6 - 1.0E-6 USD |
52 Week Range | 1.0E-6 - 0.0001 USD |
Volume | 50K USD |
Avg. Volume | 0 USD |
Market Cap | 157 USD |
Beta (5Y Monthly) | 4.103169 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
EPRSQ Valuation Measures
Enterprise Value | -6012974 USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.00010615281 |
Price/Book (mrq) | 1.001001E-6 |
Enterprise Value/Revenue | -4.066 |
Enterprise Value/EBITDA | 0.11 |
Trading Information
EPIRUS Biopharmaceuticals Stock Price History
Beta (5Y Monthly) | 4.103169 |
52-Week Change | 0% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.0001 USD |
52 Week Low | 1.0E-6 USD |
50-Day Moving Average | 0.0001 USD |
200-Day Moving Average | 0.0001 USD |
EPRSQ Share Statistics
Avg. Volume (3 month) | 0 USD |
Avg. Daily Volume (10-Days) | 0 USD |
Shares Outstanding | 26.18M |
Float | 21.73M |
Short Ratio | 0.07 |
% Held by Insiders | 0% |
% Held by Institutions | 0% |
Shares Short | 252.54K |
Short % of Float | 1.08% |
Short % of Shares Outstanding | 0.95% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2015 |
Most Recent Quarter (mrq) | March 31, 2016 |
Next Fiscal Year End | December 31, 2016 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -3744.82% |
Gross Margin | 91.54% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -45.30% |
Return on Equity (ttm) | -122.12% |
Income Statement
Revenue (ttm) | 1.48M USD |
Revenue Per Share (ttm) | 0.06 USD |
Quarterly Revenue Growth (yoy) | 3112.00% |
Gross Profit (ttm) | 576K USD |
EBITDA | -54598000 USD |
Net Income Avi to Common (ttm) | -60933000 USD |
Diluted EPS (ttm) | -0.09 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 20.87M USD |
Total Cash Per Share (mrq) | 0.8 USD |
Total Debt (mrq) | 14.85M USD |
Total Debt/Equity (mrq) | 56.76 USD |
Current Ratio (mrq) | 0.788 |
Book Value Per Share (mrq) | 0.999 |
Cash Flow Statement
Operating Cash Flow (ttm) | -49009000 USD |
Levered Free Cash Flow (ttm) | -17827624 USD |
Profile of EPIRUS Biopharmaceuticals
Country | United States |
State | MA |
City | Boston |
Address | 699 Boylston Street |
ZIP | 02116 |
Phone | 617-600-3497 |
Website | https://epirusbiopharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 73 |
EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.
Q&A For EPIRUS Biopharmaceuticals Stock
What is a current EPRSQ stock price?
EPIRUS Biopharmaceuticals EPRSQ stock price today per share is 0.0000 USD.
How to purchase EPIRUS Biopharmaceuticals stock?
You can buy EPRSQ shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for EPIRUS Biopharmaceuticals?
The stock symbol or ticker of EPIRUS Biopharmaceuticals is EPRSQ.
Which industry does the EPIRUS Biopharmaceuticals company belong to?
The EPIRUS Biopharmaceuticals industry is Biotechnology.
How many shares does EPIRUS Biopharmaceuticals have in circulation?
The max supply of EPIRUS Biopharmaceuticals shares is 0.
What is EPIRUS Biopharmaceuticals Price to Earnings Ratio (PE Ratio)?
EPIRUS Biopharmaceuticals PE Ratio is 0.00000000 now.
What was EPIRUS Biopharmaceuticals earnings per share over the trailing 12 months (TTM)?
EPIRUS Biopharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the EPIRUS Biopharmaceuticals company belong to?
The EPIRUS Biopharmaceuticals sector is Healthcare.